ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2026
Associations between Metabolomic Signatures of Persistent Smoking Effects and Lung Cancer Risk among Former Smokers.
Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundSmoking-related metabolic perturbations may persist long after smoking cessation. We aimed to develop a metabolomic signature for persistent smoking (MSPS) and prospectively assess its association with lung cancer risk among former smokers.
methodsGlobal untargeted metabolomic data from 1,732 participants of the Shanghai Men's Health Study (SMHS) and Southern Community Cohort Study (SCCS) were used to construct MSPS. Linear regression and elastic net regression were applied to select persistent smoking-related metabolites and develop MSPS. We evaluated the association of MSPS with lung cancer via conditional logistic regression among 229 case-control pairs nested in former smokers of the SCCS and SMHS.
resultsWe identified 130 metabolites significantly associated with current smoking status (PFDR < 0.05). After excluding tobacco-specific metabolites, we selected 16 metabolites associated with former smoking (6 lipids, 6 xenobiotics, 2 amino acids, and 2 carbohydrates) to derive the MSPS. The MSPS showed a significant association with increased lung cancer risk [odds ratio (OR); 95% confidence interval (CI), 1.44 (1.15-1.81) per standard deviation (SD)], independent of smoking pack-years and quitting duration. The association was consistently seen in Whites (OR = 1.91; 95% CI, 1.19-3.07 per SD), Blacks (OR = 1.66; 95% CI, 1.07-2.56 per SD), and Asians (OR = 1.15; 95% CI, 0.81-1.63 per SD).
conclusionsWe developed an MSPS that was robustly associated with lung cancer risk independent of smoking history for former smokers. If validated, the MSPS can be applied to identify former smokers at high risk of developing lung cancer. IMPACT: The MSPS provides a novel tool to stratify lung cancer risk among former smokers, beyond current guidelines based on smoking history.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.